Noninvasive screening and management of cirrhotic portal hypertension

Xiaofeng ZHANG; Jinjun CHEN

doi:10.3969/j.issn.1001-5256.2022.06.002

Volume 38 Issue 6

Jun. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(6): 1220-1223

PDF( 1854 KB)

Noninvasive screening and management of cirrhotic portal hypertension

DOI: 10.3969/j.issn.1001-5256.2022.06.002

Xiaofeng ZHANG^{1, 2},
Jinjun CHEN^{1, 2, 3
,
,
,}

1.
Hepatology Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China
2.
Department of Hepatology, Zengcheng Branch of Nanfang Hospital, Southern Medical University, Guangzhou 511300, China
3.
Hepatology Institute of Guangdong Province, Guangzhou 510515, China

More Information

Corresponding author: CHEN Jinjun, chjj@smu.edu.cn (ORCID: 0000-0003-4275-9149)
Received Date: 2022-03-06
Accepted Date: 2022-04-12
Published Date: 2022-06-20

Abstract

Abstract

Portal hypertension-related complications are the major cause of death in patients with advanced chronic liver disease (ACLD). Hepatic venous pressure gradient is the golden standard for assessing portal hypertension, and upper gastrointestinal endoscopy is an important method for screening and assessing esophageal and gastric varices and its severity; both methods are invasive and inappropriate for portal hypertension screening and monitoring. Noninvasive approaches, such as transient elastography, acoustic radiation force impulse, and shear wave elastography, have been used for the evaluation of portal hypertension in ACLD patients, especially the screening, stratified diagnosis, and monitoring of clinically significant portal hypertension.
- Liver Cirrhosis,
- Hypertension, Portal,
- Elasticity Imaging Techniques

FullText(HTML)

References(35)

References

[1]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno Ⅶ-Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[2]	D'AMICO G, PASTA L, MORABITO A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients[J]. Aliment Pharmacol Ther, 2014, 39(10): 1180-1193. DOI: 10.1111/apt.12721.
[3]	D'AMICO G, GARCIA-TSAO G, PAGLIARO L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies[J]. J Hepatol, 2006, 44(1): 217-231. DOI: 10.1016/j.jhep.2005.10.013.
[4]	RIPOLL C, GROSZMANN R, GARCIA-TSAO G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis[J]. Gastroenterology, 2007, 133(2): 481-488. DOI: 10.1053/j.gastro.2007.05.024.
[5]	de FRANCHIS R, Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno Ⅵ Consensus Workshop: Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol, 2015, 63(3): 743-752. DOI: 10.1016/j.jhep.2015.05.022.
[6]	PAPATHEODORIDI M, HIRIART JB, LUPSOR-PLATON M, et al. Refining the Baveno Ⅵ elastography criteria for the definition of compensated advanced chronic liver disease[J]. J Hepatol, 2021, 74(5): 1109-1116. DOI: 10.1016/j.jhep.2020.11.050.
[7]	JI Y, LI J, HE Q, et al. Baveno Ⅵ elastography criteria for ruling in cACLD works well in MAFLD patients[J]. J Hepatol, 2021, 75(5): 1243-1245. DOI: 10.1016/j.jhep.2021.06.003.
[8]	ZHOU YJ, GAO F, LIU WY, et al. Screening for compensated advanced chronic liver disease using refined Baveno Ⅵ elastography cutoffs in Asian patients with nonalcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2021, 54(4): 470-480. DOI: 10.1111/apt.16487.
[9]	VIZZUTTI F, ARENA U, ROMANELLI RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis[J]. Hepatology, 2007, 45(5): 1290-1297. DOI: 10.1002/hep.21665.
[10]	SHI KQ, FAN YC, PAN ZZ, et al. Transient elastography: a meta-analysis of diagnostic accuracy in evaluation of portal hypertension in chronic liver disease[J]. Liver Int, 2013, 33(1): 62-71. DOI: 10.1111/liv.12003.
[11]	REIBERGER T, FERLITSCH A, PAYER BA, et al. Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis[J]. J Gastroenterol, 2012, 47(5): 561-568. DOI: 10.1007/s00535-011-0517-4.
[12]	PONS M, AUGUSTIN S, SCHEINER B, et al. Noninvasive diagnosis of portal hypertension in patients with compensated advanced chronic liver disease[J]. Am J Gastroenterol, 2021, 116(4): 723-732. DOI: 10.14309/ajg.0000000000000994.
[13]	KIM BK, HAN KH, PARK JY, et al. A liver stiffness measurement-based, noninvasive prediction model for high-risk esophageal varices in B-viral liver cirrhosis[J]. Am J Gastroenterol, 2010, 105(6): 1382-1390. DOI: 10.1038/ajg.2009.750.
[14]	ABRALDES JG, BUREAU C, STEFANESCU H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate"study[J]. Hepatology, 2016, 64(6): 2173-2184. DOI: 10.1002/hep.28824.
[15]	STAFYLIDOU M, PASCHOS P, KATSOULA A, et al. Performance of Baveno Ⅵ and expanded Baveno Ⅵ criteria for excluding high-risk varices in patients with chronic liver diseases: a systematic review and Meta-analysis[J]. Clin Gastroenterol Hepatol, 2019, 17(9): 1744-1755. e11. DOI: 10.1016/j.cgh.2019.04.062.
[16]	WANG H, WEN B, CHANG X, et al. Baveno Ⅵ criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis[J]. J Hepatol, 2021, 74(3): 584-592. DOI: 10.1016/j.jhep.2020.09.034.
[17]	THABUT D, BUREAU C, LAYESE R, et al. Validation of Baveno Ⅵ criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained response to antiviral therapy[J]. Gastroenterology, 2019, 156(4): 997-1009. e5. DOI: 10.1053/j.gastro.2018.11.053.
[18]	DING NS, NGUYEN T, ISER DM, et al. Liver stiffness plus platelet count can be used to exclude high-risk oesophageal varices[J]. Liver Int, 2016, 36(2): 240-245. DOI: 10.1111/liv.12916.
[19]	STEFANESCU H, GRIGORESCU M, LUPSOR M, et al. Spleen stiffness measurement using Fibroscan for the noninvasive assessment of esophageal varices in liver cirrhosis patients[J]. J Gastroenterol Hepatol, 2011, 26(1): 164-170. DOI: 10.1111/j.1440-1746.2010.06325.x.
[20]	COLECCHIA A, RAVAIOLI F, MARASCO G, et al. A combined model based on spleen stiffness measurement and Baveno Ⅵ criteria to rule out high-risk varices in advanced chronic liver disease[J]. J Hepatol, 2018, 69(2): 308-317. DOI: 10.1016/j.jhep.2018.04.023.
[21]	ROBIC MA, PROCOPET B, MÉTIVIER S, et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study[J]. J Hepatol, 2011, 55(5): 1017-1024. DOI: 10.1016/j.jhep.2011.01.051.
[22]	LEE HW, YIP TC, TSE YK, et al. Hepatic decompensation in cirrhotic patients receiving antiviral therapy for chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2021, 19(9): 1950-1958. e7. DOI: 10.1016/j.cgh.2020.08.064.
[23]	COLECCHIA A, COLLI A, CASAZZA G, et al. Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study[J]. J Hepatol, 2014, 60(6): 1158-1164. DOI: 10.1016/j.jhep.2014.02.024.
[24]	SALZL P, REIBERGER T, FERLITSCH M, et al. Evaluation of portal hypertension and varices by acoustic radiation force impulse imaging of the liver compared to transient elastography and AST to platelet ratio index[J]. Ultraschall Med, 2014, 35(6): 528-533. DOI: 10.1055/s-0034-1366506.
[25]	KIM HY, SO YH, KIM W, et al. Non-invasive response prediction in prophylactic carvedilol therapy for cirrhotic patients with esophageal varices[J]. J Hepatol, 2019, 70(3): 412-422. DOI: 10.1016/j.jhep.2018.10.018.
[26]	JANSEN C, BOGS C, VERLINDEN W, et al. Shear-wave elastography of the liver and spleen identifies clinically significant portal hypertension: A prospective multicentre study[J]. Liver Int, 2017, 37(3): 396-405. DOI: 10.1111/liv.13243.
[27]	ZHU YL, DING H, FU TT, et al. Portal hypertension in hepatitis B-related cirrhosis: Diagnostic accuracy of liver and spleen stiffness by 2-D shear-wave elastography[J]. Hepatol Res, 2019, 49(5): 540-549. DOI: 10.1111/hepr.13306.
[28]	TREBICKA J, GU W, DE LEDINGHEN V, et al. Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease[J]. Gut, 2022, 71(2): 402-414. DOI: 10.1136/gutjnl-2020-323419.
[29]	SINGH S, VENKATESH SK, WANG Z, et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data[J]. Clin Gastroenterol Hepatol, 2015, 13(3): 440-451. e6. DOI: 10.1016/j.cgh.2014.09.046.
[30]	HUWART L, SEMPOUX C, SALAMEH N, et al. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index[J]. Radiology, 2007, 245(2): 458-466. DOI: 10.1148/radiol.2452061673.
[31]	WAGNER M, HECTORS S, BANE O, et al. Noninvasive prediction of portal pressure with MR elastography and DCE-MRI of the liver and spleen: Preliminary results[J]. J Magn Reson Imaging, 2018, 48(4): 1091-1103. DOI: 10.1002/jmri.26026.
[32]	EISENBREY JR, DAVE JK, HALLDORSDOTTIR VG, et al. Chronic liver disease: noninvasive subharmonic aided pressure estimation of hepatic venous pressure gradient[J]. Radiology, 2013, 268(2): 581-588. DOI: 10.1148/radiol.13121769.
[33]	GUPTA I, EISENBREY JR, MACHADO P, et al. Diagnosing portal hypertension with noninvasive subharmonic pressure estimates from a US contrast agent[J]. Radiology, 2021, 298(1): 104-111. DOI: 10.1148/radiol.2020202677.
[34]	SHARMA S, AGARWAL S, GUNJAN D, et al. Deciding among noninvasive tools for predicting varices needing treatment in chronic liver disease: an analysis of Asian cohort[J]. Am J Gastroenterol, 2020, 115(10): 1650-1656. DOI: 10.14309/ajg.0000000000000722.
[35]	CALVARUSO V, CACCIOLA I, LICATA A, et al. Is transient elastography needed for noninvasive assessment of high-risk varices? The REAL experience[J]. Am J Gastroenterol, 2019, 114(8): 1275-1282. DOI: 10.14309/ajg.0000000000000266.

Relative Articles

[1]	Zhiru WANG, Wenjing ZHAO, Xi CHEN. Effect and mechanism of gallic acid on the proliferation， migration， invasion， and apoptosis of human hepatocellular carcinoma HepG2 cells[J]. Journal of Clinical Hepatology, 2025, 41(3): 493-498. doi: 10.12449/JCH250315
[2]	Junzhe CAI, Songbai LIU, Xiaobin FEI, Peng LIU, Changhao ZHU, Xing WANG, Yaozhen PAN. Effect of ankyrin-repeat domain-containing protein 22 on human hepatoma cells and its mechanism[J]. Journal of Clinical Hepatology, 2024, 40(5): 989-996. doi: 10.12449/JCH240519
[3]	Lina BAI, Ying LIU, Chunxiao TANG, Hongxin PIAO, Zhenhua LIN, Wanshan YANG, Aihua JIN. Mechanism of carrimycin in regulating the biological function of pancreatic cancer cells[J]. Journal of Clinical Hepatology, 2022, 38(12): 2793-2801. doi: 10.3969/j.issn.1001-5256.2022.12.020
[4]	Jianan ZHAO, Jinghua PENG, Ping LIU, Yiyang HU. Effect of Cordyceps polysaccharides on hepatocyte apoptosis induced by tumor necrosis factor-α[J]. Journal of Clinical Hepatology, 2021, 37(6): 1368-1372. doi: 10.3969/j.issn.1001-5256.2021.06.029
[5]	Lu Qian, Cheng Xin, Xia ZhenGuo, Chen Zhong. Effect of proteasome subunit beta type 4 on the proliferation and viability of human liver cancer SMMC7721 cells[J]. Journal of Clinical Hepatology, 2020, 36(3): 592-595. doi: 10.3969/j.issn.1001-5256.2020.03.024
[6]	Wang ZeXin, Guan LiJun, Li JianMing, Wang ZhiChao, Xue MengRuo, Qin XiaoJun. Effect of targeted regulation of the Wnt2 gene by microRNA( microRNA-21) on the proliferation and migration of HepG2 hepatoma cells[J]. Journal of Clinical Hepatology, 2020, 36(4): 803-807. doi: 10.3969/j.issn.1001-5256.2020.04.019
[7]	Xiao ErHui, Ning HuiBin, Kang YueHua, Yin Hui, Ma Li, Mao ZhongShan, Zhao Yan, Shang Jia. Downregulation of miR-196b in regulating the growth and apoptosis of hepatoma cells by targeting nuclear apoptosis-inducing factor 1[J]. Journal of Clinical Hepatology, 2020, 36(10): 2230-2235. doi: 10.3969/j.issn.1001-5256.2020.10.014
[8]	Zhang Yang, Chen ShuYing, Xu GuangRu. Effect of extracellular ubiquitin on the proliferation,invasion,and migration of hepatoma cells[J]. Journal of Clinical Hepatology, 2020, 36(6): 1289-1292. doi: 10.3969/j.issn.1001-5256.2020.06.020
[9]	Zhu YueKun, Zhao XianQi, Wang DaWei, Zhang Wei, Tian MaoLin, Li ZhengTian, Zhao Long, Li Chao, Jiang HongChi. Effect of cyclooxygenase-2 antisense RNA combined with celecoxib on the proliferation and apoptosis of hepatoma cells[J]. Journal of Clinical Hepatology, 2018, 34(12): 2614-2618. doi: 10.3969/j.issn.1001-5256.2018.12.021
[10]	Li YingYing, Zhan LiFen, Ceng ZheChao, Xu Shen. Effect of lobaplatin on proliferation and apoptosis of hepatocellular carcinoma HepG2 cells and related mechanism of action[J]. Journal of Clinical Hepatology, 2018, 34(4): 784-788. doi: 10.3969/j.issn.1001-5256.2018.04.018
[11]	Sha Liang, He JianBo, Li KeZhi, Chen Chuang, Huang Shan, Zhao YinNong, Lian Fang, Wu GuoBin. Influence of specific down-regulation of LKB1 expression on invasion and migration of hepatoma cells[J]. Journal of Clinical Hepatology, 2017, 33(5): 875-879. doi: 10.3969/j.issn.1001-5256.2017.05.016
[12]	Geng YaJun, Li ShuDong, Liu ShenZheng, Ren JianJun, Zhang Tong. Inhibitory effect of microRNA-149-5p in the proliferation and migration of HepG2 and Bel-7402 hepatoma cells[J]. Journal of Clinical Hepatology, 2017, 33(6): 1126-1130. doi: 10.3969/j.issn.1001-5256.2017.06.022
[13]	Zhang ChaoYa, Zhao XiangXuan, Lu ZaiMing, Guo QiYong. Research advances in sorafenib- induced apoptotic signaling pathways in liver cancer cells[J]. Journal of Clinical Hepatology, 2016, 32(4): 816-820. doi: 10.3969/j.issn.1001-5256.2016.04.048
[14]	Pan LiuLan, Jia ShengNan, Ma JingTing, Tai JingHua, Jin ZhenJing. Effect of decoy receptor 3 gene on hepatocyte apoptosis[J]. Journal of Clinical Hepatology, 2016, 32(7): 1330-1333. doi: 10.3969/j.issn.1001-5256.2016.07.023
[15]	Du SenRong, Mao XiaoRong, Xiao Ping, Chen Hong. Effects of PARP-1 inhibitors AG-014699 and AZD2281 on proliferation and apoptosis of human hepatoma cell line HepG2[J]. Journal of Clinical Hepatology, 2015, 31(6): 943-946. doi: 10.3969/j.issn.1001-5256.2015.06.027
[16]	Xu Li, Ma KeXin, Dong Bing, Liu HaiWang, Liu QinLong, Gao ZhenMing, Sun DeGuang, Zhang RiXin, Wang HaiBo, Wang LiMing, Liang Rui. Regulatory effect of miRNAs on apoptosis, migration, and cell cycle of hepatocellular carcinoma cells[J]. Journal of Clinical Hepatology, 2013, 29(7): 554-557.
[17]	Shen Bo, Nie YuQiang. Peroxisome proliferator- activated receptor gamma inhibits liver cancer proliferation and metastasis in vitro[J]. Journal of Clinical Hepatology, 2013, 29(9): 702-706. doi: 10.3969/j.issn.1001-5256.2013.09.018
[18]	Jia XiaoLi, Shi JuanJuan, Feng Ting, Cheng YanAn, Wang Rui, Liu JingKun, Dang ShuangSuo. Effects of guggulsterone on proliferation and apoptosis of HepG2 human hepatocellular carcinoma cells[J]. Journal of Clinical Hepatology, 2013, 29(6): 452-455.
[19]	Tai BoJun, Yao Min, Gu Xing, Shi Yun, Yu DanDan, Chen Jie, Zheng WenJie, Yao DengFu, Lu ShaoLin. Effects of silencing glypican- 3 gene transcription on proliferation and apoptosis of hepatoma cells[J]. Journal of Clinical Hepatology, 2013, 29(11): 863-866. doi: 10.3969/j.issn.1001-5256.2013.10.015
[20]	Qiao ChunPing, Chen YueXiang. Advances in study of the relationship between apoptosis and alcoholic liver disease[J]. Journal of Clinical Hepatology, 2012, 28(5): 386-390.

Supplements(0)

Cited By

Cited by

Periodical cited type(7)

1.	李慧萍，郑雪琴，赵群，唐建江. Ⅲ型前胶原、Ⅳ型胶原、层黏连蛋白和透明质酸酶在诊断肝纤维化程度中的应用. 检验医学与临床. 2019(05): 666-668 .
2.	吴一鸣，高树兴，殷新光. 核素首次通过法测定肝动脉血流指数预测日本血吸虫病肝纤维化程度?. 中国肝脏病杂志(电子版). 2018(02): 49-54 .
3.	柯叶芳，高国生，朱喆，陈必成. 血清腺苷脱氨酶对慢性HBV感染者显著肝纤维化的诊断价值. 临床肝胆病杂志. 2018(04): 760-763 . 本站查看
4.	吴一鸣，高树兴，殷新光. 测定肝动脉血流指数预测血吸虫肝纤维化的临床研究. 世界华人消化杂志. 2018(07): 434-440 .
5.	胡烨，张国. 肝纤维化诊断及其严重程度评估. 实用肝脏病杂志. 2017(01): 13-16 .
6.	王娉娉，杨芬. 生物组织弹性成像方法及其新技术进展. 激光生物学报. 2016(06): 501-508+514 .
7.	牟文倩，李春艳，陈延平. 继发性血色病1例报告. 临床肝胆病杂志. 2016(09): 1789-1790 . 本站查看

Other cited types(4)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (943) PDF downloads(170)

Noninvasive screening and management of cirrhotic portal hypertension

DOI: 10.3969/j.issn.1001-5256.2022.06.002